Clearmind Medicine Completes Treatment and Follow-up for 18 Participants in Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder.

Clearmind Medicine has completed treatment and follow-up for 18 participants in its ongoing Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The company has also expanded enrollment at its Tel Aviv center, with four additional participants successfully treated.